Congrats to Blue Shield of California for taking a step in the right direction! They just announced their partnership with Fresenius Kabi and Evio to offer Idacio, a biosimilar for chronic autoimmune diseases, at $525 per monthly dose. Notably, most members will have no out-of-pocket costs for this medication. In the news release, CEO Paul Markovich stated, "We will no longer take part in a pharmacy system that is designed to maximize profit instead of quality, convenience, and cost-effectiveness for consumers." This direct approach, coupled with their Pharmacy Care Reimagined program, demonstrates insurers' ability to drive real change. It marks progress towards more affordable, transparent healthcare—a vision SmithRx shares. #healthcareinnovation #affordablehealthcare #biosimilars #pharmacybenefits
Big news! We’re proud to announce a major step forward in transforming pharmacy care: starting January 1, we’ll offer our members a biosimilar version of Humira – one of the most widely prescribed medicines in the U.S. – at a fraction of the cost. Through our collaboration with Fresenius Kabi and Evio Pharmacy Solutions, most of our Commercial members will have access to this FDA-approved biosimilar at a $0 co-pay. It’s all part of our Pharmacy Care Reimagined initiative, which is transforming pharmacy care to be more affordable and transparent. Learn more at https://bit.ly/3zI4xSM #WellAhead #PharmacyCareReimagined #AffordableCare #Biosimilars #HealthCareTransformation